Impact of Severe Infections on Non-Relapse Mortality after Allogeneic HCT: A Post-Hoc Analysis of a Randomized Phase II Study Comparing Post-Transplantation Cyclophosphamide (PTCy) and Non-Ptcy-Based GVHD Prophylaxis | Synapse
March 3, 2026
Impact of Severe Infections on Non-Relapse Mortality after Allogeneic HCT: A Post-Hoc Analysis of a Randomized Phase II Study Comparing Post-Transplantation Cyclophosphamide (PTCy) and Non-Ptcy-Based GVHD Prophylaxis
Puntos clave
Severe infections significantly increase non-relapse mortality rates in allogeneic HCT patients, indicating their critical impact on outcomes.
The study specifically reveals a concerning trend where infections contribute to worsening mortality despite prophylactic measures used.
Observational analysis of a randomized phase II trial comparing post-transplantation cyclophosphamide and non-PTCy-based GVHD prophylaxis was conducted.
These findings highlight the need to develop better strategies for preventing severe infections post-transplant, as they may lead to higher mortality rates.